BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Transcription profiling by array of human prostate LNCaP cells over a time course of androgen deprivation

Dataset: Transcription profiling by array of human prostate LNCaP cells over a time course of androgen deprivation

Following androgen ablation therapy (AAT), the vast majority of prostate cancer patients develop treatment resistance with a median time...

Registered by ArrayExpress Uploader
View Dataset

Following androgen ablation therapy (AAT), the vast majority of prostate cancer patients develop treatment resistance with a median time of 18-24 months to disease progression. To identify molecular targets that aid in prostate cancer cell survival and contribute to the androgen independent phenotype, we evaluated changes in LNCaP cell gene expression during 12 months of androgen deprivation. At time points reflecting critical growth and phenotypic changes, we performed Affymetrix expression array analysis to examine the effects of androgen deprivation during the acute response, during the period of apparent quiescence, and during the emergence of highly proliferative, androgen-independent prostate cancer cells (LNCaP-AI). We discovered alterations in gene expression for a host of molecules associated with promoting prostate cancer cell growth and survival, regulating cell cycle progression, apoptosis and adrenal androgen metabolism, in addition to AR co-regulators and markers of neuroendocrine disease. These findings illustrate the complexity and unpredictable nature of cancer cell biology and contribute greatly to our understanding of how prostate cancer cells likely survive AAT. The value of this longitudinal approach lies in the ability to examine gene expression changes throughout the cellular response to androgen deprivation; it provides a more dynamic illustration of those genes which contribute to disease progression in addition to specific genes which constitute a malignant androgen-independent phenotype. In conclusion, it is of great importance that we employ new approaches, such as the one proposed here, to continue exploring the cellular mechanisms of therapy resistance and identify promising targets to improve cancer therapeutics. Experiment Overall Design: To identify molecular targets that aid in prostate cancer cell survival and contribute to the androgen independent phenotype, we evaluated changes in LNCaP cell gene expression during 12 months of androgen deprivation. At time points reflecting critical growth and phenotypic changes, we performed Affymetrix expression array analysis to examine the effects of androgen deprivation during the acute response, during the period of apparent quiescence, and during the emergence of highly proliferative, androgen-independent prostate cancer cells (LNCaP-AI).

Species:
human

Samples:
16

Source:
E-GEOD-8702

PubMed:
18302219

Updated:
Dec.12, 2014

Registered:
Sep.22, 2014


Factors: (via ArrayExpress)
Sample growth condition sampling time point
GSE8702GSM215645 androgen deficient media 11
GSE8702GSM215645 androgen deficient media 11
GSE8702GSM215643 androgen deficient media 12
GSE8702GSM215643 androgen deficient media 12
GSE8702GSM215637 androgen deficient media 1
GSE8702GSM215637 androgen deficient media 1
GSE8702GSM215634 androgen deficient media 3
GSE8702GSM215634 androgen deficient media 3
GSE8702GSM215640 androgen deficient media 5
GSE8702GSM215640 androgen deficient media 5
GSE8702GSM215642 complete media 12
GSE8702GSM215636 complete media 1
GSE8702GSM215633 complete media 3
GSE8702GSM215639 complete media 5
GSE8702GSM215647 complete media 0
GSE8702GSM215647 complete media 0

Tags

  • androgen
  • cancer
  • cell
  • disease
  • longitudinal
  • median
  • prostate
  • prostate cancer

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use